

# Hirokazu Taniguchi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8337044/hirokazu-taniguchi-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

457  
citations

12  
h-index

20  
g-index

43  
ext. papers

746  
ext. citations

6.4  
avg, IF

3.55  
L-index

#	Paper	IF	Citations
40	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , <b>2019</b> , 10, 259	17.4	116
39	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. <i>Cancer Research</i> , <b>2019</b> , 79, 1658-1670	10.1	44
38	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2244-2256	12.9	36
37	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 4607	17.4	31
36	Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 175-180	3.2	27
35	Targeted Therapies and Biomarkers in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 741	5.3	26
34	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , <b>2017</b> , 108, 53-60	6.9	20
33	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring Mutations. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 17-25	6.1	19
32	Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 341-346	3.2	14
31	Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. <i>Cancer Science</i> , <b>2017</b> , 108, 1378-1385	6.9	13
30	Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum. <i>Internal Medicine</i> , <b>2017</b> , 56, 979-982	1.1	13
29	Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	13
28	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 752-765	8.9	12
27	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 947-956	6.1	9
26	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1522-1524	3.2	7
25	Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 706-709	3.2	6
24	Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup. <i>Gut</i> , <b>2020</b> ,	19.2	5

23	Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 577-581	3.2	5
22	Small molecule inhibitor of HSP47 prevents pro-fibrotic mechanisms of fibroblasts in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2020</b> , 530, 561-565	3.4	5
21	A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 497-502	3.5	4
20	Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1972-1978	3.2	3
19	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 170	22.4	3
18	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. <i>Cell Reports</i> , <b>2022</b> , 39, 110814	10.6	3
17	Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1305-1311	3.2	2
16	Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1764-1769	3.2	2
15	Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab. <i>Respirology Case Reports</i> , <b>2013</b> , 1, 14-6	0.9	2
14	Cooperative participation of epigenomic and genomic alterations in the clinicopathological diversity of gastric adenocarcinomas: significance of cell adhesion and epithelial-mesenchymal transition-related signaling pathways. <i>Carcinogenesis</i> , <b>2020</b> , 41, 1473-1484	4.6	2
13	Presence of heat shock protein 47-positive fibroblasts in cancer stroma is associated with increased risk of postoperative recurrence in patients with lung cancer. <i>Respiratory Research</i> , <b>2020</b> , 21, 234	7.3	2
12	Risk for lymph node metastasis in Epstein-Barr virus-associated gastric carcinoma with submucosal invasion. <i>Digestive Endoscopy</i> , <b>2021</b> , 33, 592-597	3.7	2
11	Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1126-1130	3.2	2
10	Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1059-1064	3.5	1
9	In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , <b>2017</b> , 6, 2972-2983	4.8	1
8	Secondary EML4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report. <i>Japanese Journal of Clinical Oncology</i> , <b>2014</b> , 44, 593-600	2.8	1
7	Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 389-393	3.2	1
6	Changes in Immunohistochemical Protein Levels in Anaplastic Lymphoma Kinase-positive Lung Adenocarcinoma Possibly due to Chemo-radiotherapy. <i>Internal Medicine</i> , <b>2016</b> , 55, 1775-8	1.1	1

5	Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
4	Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 272-276	3.2	1
3	Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2300-2306	3.2	1
2	Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
1	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 5	9.8	0